President Trump nominated White House domestic policy aide Dr. Heidi Overton in mid-August 2026 to succeed former FDA Commissioner Marty Makary, who resigned in May amid agency staffing losses exceeding 3,000 employees and leadership turnover. Overton, a physician with prior roles at the America First Policy Institute and involvement in the administration’s Make America Healthy Again priorities on vaccines, dietary guidelines, and drug pricing, must secure Senate confirmation. The Senate Health, Education, Labor and Pensions Committee, chaired by Sen. Bill Cassidy, scheduled her confirmation hearing for September 24; Cassidy has voiced strong concerns over her participation in a recent vaccine-related executive order and limited managerial experience. Democrats have signaled opposition, while the narrow Republican Senate majority will determine the outcome. Resolution hinges on committee advancement and floor support.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$21,961 Vol.
September 30
7%
October 31
35%
November 30
30%
December 31
63%
$21,961 Vol.
September 30
7%
October 31
35%
November 30
30%
December 31
63%
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
Market Opened: Aug 20, 2026, 5:43 PM ET
Resolver
0x65070BE91...If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
Resolver
0x65070BE91...President Trump nominated White House domestic policy aide Dr. Heidi Overton in mid-August 2026 to succeed former FDA Commissioner Marty Makary, who resigned in May amid agency staffing losses exceeding 3,000 employees and leadership turnover. Overton, a physician with prior roles at the America First Policy Institute and involvement in the administration’s Make America Healthy Again priorities on vaccines, dietary guidelines, and drug pricing, must secure Senate confirmation. The Senate Health, Education, Labor and Pensions Committee, chaired by Sen. Bill Cassidy, scheduled her confirmation hearing for September 24; Cassidy has voiced strong concerns over her participation in a recent vaccine-related executive order and limited managerial experience. Democrats have signaled opposition, while the narrow Republican Senate majority will determine the outcome. Resolution hinges on committee advancement and floor support.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions